Multi-antigen Specific T cells post-Hematopoietic Stem Cell Transplant to Enhance anti-Leukemia and anti-Viral Immunity in vivo

Momentum Fellow (2021-2023)

Hannah Kinoshita, MD, Children's National Hospital

Hannah Kinoshita, MD

Dr. Kinoshita is evaluating the immunobiology of multi-antigen specific T-cell therapy infused to patients to reduce the two most common causes of morbidity and mortality following stem cell transplant—cancer relapse and infection.

published research

Kinoshita H, Mandava M, Jensen-Wachspress MA, Lang H, Joy E, Tanna J, McCann CD, O’Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña BJ, Mahadeo KM, Bollard CM, Keller MD, Abraham AA. Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease. Blood Adv. 2022.

Kinoshita H, Bollard CM, Toner K. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? Semin Hematol. 2023.